A
Asarina Pharma
Developing novel and targeted products to treat women with severe symptoms associated with the menstrual cycle
About Asarina Pharma
Asarina Pharma is a biopharmaceutical company focused on developing innovative treatments for menstrual migraine and neuropsychiatric disorders. The company operates in the healthcare and pharmaceutical market, primarily targeting women suffering from menstrual migraine, a condition that affects approximately 50 million women worldwide. Asarina Pharma's core product, Sepranolone, is a novel compound that modulates the neurochemical GABA, which plays a crucial role in reducing stress, fear, and anxiety levels. Sepranolone has shown promise in clinical trials for its safety and efficacy in treating menstrual migraine and is also being tested for Tourette syndrome.
Asarina Pharma's business model involves the research, development, and commercialization of Sepranolone. The company generates revenue through the sale of its pharmaceutical products and potentially through licensing agreements and partnerships with other pharmaceutical companies. By addressing unmet medical needs with a focus on safety and efficacy, Asarina Pharma aims to improve the quality of life for patients suffering from debilitating conditions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2006
- Headquarters
- Solna kommun, Sweden
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Kurma Partners
Eurazeo
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
4 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Asarina Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asarina Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.